CFTR and Anxiety: In addition, the potential clinical effectiveness of a lower dose strategy based on this Phase 2 study, allowed us to develop an adaptive strategy where we adopted a dose reduction protocol in the subgroup of patients with self-reported intense anxiety, irritability, sleep disturbance and/or mental slowness, in an attempt to minimize AEs while continuing CFTR modulator therapy.